|Videos|May 5, 2017
Immunotherapies Show Promise in Small-Cell Lung Cancer
Author(s)Gregory Peter Kalemkerian, MD
This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab.
Advertisement
Immunotherapy has shown efficacy in lung cancer, with several drugs already approved for patients with non–small-cell lung cancer (anti–PD-1 agent nivolumab, anti–PD-L1 agents pembrolizumab and atezolizumab).
In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses immunotherapies in the small-cell lung cancer (SCLC) setting.
Kalemkerian reviews the results of several trials in SCLC, including nivolumab monotherapy or in combination with the CTLA-4 blocker ipilimumab, and pembrolizumab.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Topical Gel for Superficial Basal Cell Carcinoma
2
FDA Approves TLX101-Px for PET Imaging in Patients With Glioma
3
FDA Approves Lutetium Lu 177 Dotatate Injection for GEP-NETs
4
FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC
5